Title : Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia.

Pub. Date : 2008 Mar

PMID : 18297533






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Anti-DT(388)IL3 antibodies developed in most patients between day 15 and 30. Thymidine interleukin 3 Homo sapiens
2 DT(388)IL3 produces remissions in patients with relapsed/refractory AML and MDS with minimal toxicities, and alternate schedules of administration are needed to enhance the response rate. Thymidine interleukin 3 Homo sapiens